(NASDAQ: BTAI) Bioxcel Therapeutics's forecast annual revenue growth rate of 474.06% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 116.92%, and it is also forecast to beat the US market's average forecast revenue growth rate of 23.08%.
Bioxcel Therapeutics's revenue in 2026 is $752,000.On average, 7 Wall Street analysts forecast BTAI's revenue for 2026 to be $46,778,841, with the lowest BTAI revenue forecast at $8,572,840, and the highest BTAI revenue forecast at $94,148,159. On average, 4 Wall Street analysts forecast BTAI's revenue for 2027 to be $732,781,035, with the lowest BTAI revenue forecast at $657,965,506, and the highest BTAI revenue forecast at $803,703,794.
In 2028, BTAI is forecast to generate $3,604,748,202 in revenue, with the lowest revenue forecast at $3,463,471,290 and the highest revenue forecast at $3,710,815,233.